Stealth Peptides Inc., of Boston, reported results of a Phase I study in healthy volunteers of Bendavia, a compound that targets the mitochondrion to treat ischemia reperfusion injury. Volunteers received a single dose of Bendavia administered as an intravenous infusion over an extended period. Bendavia appears to be safe and well tolerated at the dose evaluated, with no serious adverse events reported.